Denosumab for the treatment of hiv-associated osteoporosis with fractures in a premenopausal woman

Research output: Contribution to journalArticlepeer-review

Abstract

The prevalence of osteoporosis is about three times greater in people living with HIV than in the general population. Bisphosphonates are the only class of antiresorptive drugs which have proved to be safe and effective in HIV patients. However, bisphosphonates are not recommended in women of childbearing age due to an increased rate of associated neonatal complications. To the best of our knowledge no reports on the use of denosumab in HIV-infected individuals have been published so far. We describe a 38 year-old woman with HIV, osteoporosis and vertebral fractures treated with denosumab, a monoclonal antibody targeting RANKL. After four years of treatment, bone mineral density improved, no new fractures occurred, and neither HIV reactivation nor opportunistic infections were observed. We show that denosumab could be a safe and effective approach for osteoporosis in patients with HIV and could be considered in women of childbearing age.

Original languageEnglish
Pages (from-to)54-58
Number of pages5
JournalReumatismo
Volume73
Issue number1
DOIs
Publication statusPublished - 2021

Keywords

  • Denosumab
  • HIV
  • Osteoporosis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint

Dive into the research topics of 'Denosumab for the treatment of hiv-associated osteoporosis with fractures in a premenopausal woman'. Together they form a unique fingerprint.

Cite this